Investing.com – U.S. stocks were lower after the close on Monday, as losses in the Oil & Gas, Technology and Basic Materials sectors led shares lower. At the close in NYSE, the...
Viatris Inc (VTRS) reported Q1 EPS of $0.93, $0.09 better than the analyst estimate of $0.84. Revenue for the quarter came in at $4.18 billion versus the consensus estimate of...
By Nate Raymond (Reuters) -Viatris Inc, the drugmaker formerly known as Mylan (NASDAQ:VTRS), said on Monday it had agreed to pay $264 million to resolve a class action lawsuit...
It seems like much more than just 11 days ago that St. Louis Fed President James Bullard said the US central bank needed to bump up its short-term interest rate to 1% by July 1....
We are in the middle of the fourth-quarter 2021 earnings season with corporate bigwigs of different sectors and industries of the economy releasing their financial numbers. So far...
Tuesday, January 25, 2022 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features a real-time update on the ongoing Q4...
Viatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as its anti-retroviral franchise. Its portfolio comprises approximately 1,400 approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. It operates approximately 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Buy | Sell |
| Technical Indicators | Sell | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
| Summary | Neutral | Strong Buy | Strong Buy | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 92.84 | 93.18 | 90.38 | -1.64 | -1.74% | 12.57M | NYSE | |||
| 6.94 | 7.91 | 6.75 | -8.18 | -54.11% | 21.43M | NASDAQ | |||
| 81.89 | 82.42 | 81.56 | +0.98 | +1.21% | 59.96K | NYSE | |||
| 42.28 | 42.59 | 41.77 | +0.46 | +1.10% | 849.35K | NYSE | |||
| 9.14 | 9.25 | 8.08 | +1.46 | +19.01% | 15.51M | NYSE | |||
| 100.56 | 102.40 | 99.39 | +1.81 | +1.83% | 46.07M | NASDAQ | |||
| 40.46 | 40.50 | 39.58 | +0.88 | +2.22% | 3.22M | NYSE | |||
| 130.41 | 143.70 | 128.10 | +1.96 | +1.52% | 3.80M | NYSE | |||
| 41.18 | 41.45 | 41.16 | +0.33 | +0.81% | 32.94K | NYSE | |||
| 8.34 | 8.55 | 8.31 | +0.03 | +0.36% | 2.00M | NYSE | |||
| 44.27 | 45.30 | 42.01 | +2.35 | +5.59% | 13.64M | NASDAQ | |||
| 1.2385 | 1.25 | 1.20 | +0.0485 | +4.08% | 2.58M | NYSE | |||
| 144.73 | 145.66 | 136.59 | +8.93 | +6.58% | 2.86M | NASDAQ | |||
| 199.67 | 201.50 | 198.83 | +5.18 | +2.66% | 684.52K | NASDAQ | |||
| 102.62 | 102.64 | 101.14 | +1.93 | +1.92% | 213.18K | NYSE |